<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527887</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000084</org_study_id>
    <nct_id>NCT04527887</nct_id>
  </id_info>
  <brief_title>Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)</brief_title>
  <acronym>DEcIDED</acronym>
  <official_title>Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-center, randomized, double-masked, parallel comparison, sponsored&#xD;
      study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on&#xD;
      ameliorating the signs and symptoms of dry eye disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ocular inflammation</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>As measured by change to dendritic cell density and ocular redness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>12-item scale; score ranges from 0 to 100 and is calculated by the sum of the scores for all 12 questions answered multiplied by 100, which is divided by the total number of questions answered times four</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Ocular Pain Assessment Survey (OPAS)</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>32-questions, 8-domain questionnaire using numerical rating scales to assess eye pain intensity (worse eye) in the past 24 hours and 2 weeks (worst, least and average pain intensity), frequency of eye and non-eye pain (past 24 hours and 2 weeks), non-eye pain intensity (past 24 hours and 2 weeks), impact on QoL, pre-occupation with eye and non-eye pain, aggravating factors and associated factors.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Symptom Assessment in Dry Eye scores (SANDE)</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>Score is calculated by multiplying the frequency of symptoms score with the severity of symptoms score and obtaining the square root.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Tear Break Up Time (TBUT)</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>The standard TBUT measurement will be performed by dropping a fluorescein drop to the inferior tarsal conjunctiva and waiting 30 seconds. After several blinks, the tear film will be examined. The time lapse between the last blink and the appearance of the first randomly distributed dark discontinuity in the fluorescein stained tear film will be measured three times and the mean value of the measurements will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Conjunctival staining</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>Grading of conjunctival lissamine green staining will be performed after 1 minutes of application of a lissamine green drop. Staining will be graded using the National Eye Institute (NEI) grading scheme, with a total range of 0-18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Corneal staining with fluorescein</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>Corneal fluorescein staining will be performed after 2 minutes of application of a fluorescein drop. Staining will be graded using the National Eye Institute (NEI) grading scheme, with a total range of 0-15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Schirmer II test</measure>
    <time_frame>Change from Baseline one month after intracanalicular insert implantation or punctal plug</time_frame>
    <description>Aqueous tear production will be measured by the length in millimeters that the strip wets during 5 minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intracanalicular dexamethasone insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ProLong™ collagen plugs</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>collagen plug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)</intervention_name>
    <description>Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.</description>
    <arm_group_label>Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ProLong™ collagen plugs</intervention_name>
    <description>The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.</description>
    <arm_group_label>ProLong™ collagen plugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Dry Eye Disease&#xD;
&#xD;
          -  Objective Signs (Schirmer's II test &lt;10 mm at 5 min; Tear Break-Up time (TBUT) of &lt;10&#xD;
             seconds in 1 eye; corneal fluorescein staining of .=4 in at least 1 eye; conjunctival&#xD;
             lissamine green staining of the nasal and temporal conjunctive &gt;=4 in at least 1 eye)&#xD;
&#xD;
          -  Ocular inflammation presence confirmed by In-Vivo Confocal Microscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Diabetes&#xD;
&#xD;
          -  History of ocular surgery, corneal infection, or corneal injury within the last 3&#xD;
             months&#xD;
&#xD;
          -  Active ocular allergies&#xD;
&#xD;
          -  Active ocular infection&#xD;
&#xD;
          -  Allergic to benzalkonium chloride&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedram Hamrah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Gee, MPH</last_name>
    <phone>617-636-5489</phone>
    <email>ngee@tuftsmedicalcenter.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Gee, MPH</last_name>
      <phone>617-636-5489</phone>
      <email>ngee@tuftsmedicalcenter.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael Dixon</last_name>
      <phone>617-636-1051</phone>
      <email>mdixon3@tuftsmedicalcenter.org</email>
    </contact_backup>
    <investigator>
      <last_name>Pedram Hamrah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

